Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · NOVYRA PHARMACHEM LIMITED · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
NOVYRA PHARMACHEM LIMITED
BSE: 519353
BSE: 519353
Fast Moving Consumer Goods › Fast Moving Consumer Goods › Agricultural Food & other Products › Tea & Coffee
NOVYRA PHARMACHEM LIMITED
StateQ1 FY27 filed
Last close · 28 Oct 2026₹8.08
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA— · 8.60 · —
NOVYRA PHARMACHEM LIMITED is a Agricultural Food & other Products company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| EBITDA (ex other income) | (0) | 0 | (0) | (0) | (5) |
| margin % | (10.3) | 30.1 | — | — | (5180.1) |
| Owners' profit | 0 | 0 | (0) | (0) | (5) |
| EPS, as reported (₹) | 0.00 | 0.02 | (0.03) | (0.10) | (8.49) |
| ROE % · ROCE % | 0.1 · 0.1 | 0.2 · 0.5 | (2.7) · (2.6) | (1.1) · (1.1) | (907.6) · (907.6) |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 |
| Cash from operations | (1) | 0 | (0) | (0) | (4) |
| Capex | 0 | 0 | 0 | 0 | 0 |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · NOVYRA PHARMACHEM LIMITED · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Profit before tax | (0) | (0) | (0) | (0) | 0 | (0) | (5) | (0) |
| Net profit | (0) | (0) | (0) | (0) | 0 | (0) | (5) | (0) |
| EPS (₹) | 0.00 | (0.02) | (0.08) | 0.03 | 0.00 | (0.02) | (8.43) | (0.03) |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Segment - Pharma | 0 | 9.6 |
| Segment - Real Estate | 0 | 4.8 |
| Segment - Tea Estate | 0 | 85.6 |
| Total, before eliminations | 0 | 100.0 |
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| TATA CONSUMER PRODUCT LTD | 98,980 | 60.5 | 4.27 | 33.4 | 6.7 | 7.8 | 11.8 | 14.9 |
| CCL PRODUCTS (I) LTD | 12,529 | 28.9 | 5.34 | 18.4 | 16.6 | 16.2 | 29.1 | 16.4 |
| VINTAGE COFFEE N BVRGS L | 2,229 | 28.3 | 3.92 | 21.1 | 12.7 | 14.0 | — | 20.6 |
| ANDREW YULE & CO. LTD. | 1,109 | — | 3.41 | — | (5.9) | (9.5) | (2.2) | (44.3) |
| GOODRICKE GROUP LTD. | 457 | 17.9 | 1.51 | — | 8.4 | 5.0 | — | (22.7) |
| JAYSHREE TEA & INDUSTRIES | 233 | — | 0.59 | 20.3 | (6.3) | (5.1) | 3.0 | 4.9 |
| THE P K TEA PROD CO LTD | 206 | 38.1 | 1.08 | 17.7 | 2.8 | 3.2 | — | 50.0 |
| UNITED NILGIRI TEA LTD | 202 | 10.0 | 0.84 | — | 9.1 | 10.4 | — | 43.5 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 8.6 | 0.6 | 27 of 27 | 0% |
| ROCE | (907.6) | 3.0 | 26 of 26 | 0% |
| ROE | (907.6) | 2.3 | 27 of 27 | 0% |
| Debt / Equity | 0.0 | 0.2 | 1 of 26 | 84% |
| EBITDA margin | (1.0) | 11.9 | 17 of 26 | 36% |
| Profit growth | (158.4) | 18.5 | 23 of 27 | 15% |
| Market cap | 5 | 112 | 26 of 27 | 4% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · NOVYRA PHARMACHEM LIMITED · 29 October 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 23 Oct 2026 · Board to approve September quarter results on 2 November 2026 | results | low | — | — |
| 14 Oct 2026 · Reg 74(5) compliance certificate filed for Q2 FY26 | compliance | minimal | — | — |
| 25 Sept 2026 · Trading Window Closed Until Q2 FY26 Results Announcement | compliance | minimal | — | — |
| 22 Aug 2026 · Name change to Novyra Pharmachem, pivot into pharma and contract services | business updates | high | — | — |
| 11 Aug 2026 · Board meeting on Aug 14 to consider Q1 FY27 results | results | low | — | — |
| 4 Aug 2026 · Change of website address to novyrapharmachemltd.com | general | minimal | — | — |
| 13 Jul 2026 · RTA compliance certificate under SEBI Reg 74(5) for Apr-Jun 2026 | compliance | minimal | — | — |
| 26 Jun 2026 · Bansisons Tea Industries closes insider trading window | compliance | minimal | — | — |
| 26 Jun 2026 · AGM 2026: All 5 resolutions passed, capital reduction approved | board shareholder meetings | low | — | — |
| 25 Jun 2026 · 39th AGM held; Capital Reduction and MD appointment approved | board shareholder meetings | low | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in